Company intelligence / Profile preview
BioLingus
Hergiswil, Nidwalden, Switzerlandbiolingus.ch ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Preclinical
01
Overview
BioLingus has developed a patented sublingual/oral delivery platform enabling room-temperature-stable formulations of peptides and proteins. Lead assets include sublingual exenatide, liraglutide, semaglutide, insulin+, IL‑2 and IFN. The company’s technology allows non-invasive administration with rapid uptake and improved patient compliance compared to injectables. Clinical results have shown that after extensive development the required sublingual dose was reduced from ~200x injectable to just ~5–10x injectable doses for exenatide; further clinical data not detailed in public sources but multiple programs are advancing through preclinical/early clinical stages.
- Therapeutic areas
- Metabolic DisordersEndocrinologyImmunology
- Modalities
- PeptidesProteinsSmall molecules (to a lesser extent)Novel protein scaffoldsNucleotidesDomain antibodies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Open to outlicensing/platform partnerships with other companies developing peptide/protein drugs; no major pharma partners publicly disclosed yet but active business development ongoing.
Beyond the preview
Go deeper on BioLingus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioLingus.